NervGen Pharma Corp. Common stock
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.33 | $0 | -$6M |
| 2026 Q1 | -0.02 | $0 | -$8M |
| 2025 Q4 | -0.44 | $0 | -$10M |
| 2025 Q3 | -0.06 | $0 | -$5M |
| 2025 Q2 | -0.13 | $0 | -$4M |
| 2025 Q1 | -0.06 | $0 | -$4M |
| 2024 Q4 |
| -0.12 |
| $0 |
| -$4M |
| 2024 Q3 | -0.08 | $0 | -$6M |